Search - tctmd.com

Displaying 61 - 80 of 123

Sort: Relevancy | Date

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Daily News

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Michael O'Riordan

January 14, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Advertisement

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content